They include imatinib mesylate (or “Gleevec”/“Glivec”) for BCR-ABL inhibition in Chronic Myeloid Leukemia (CML) [9] and for KIT inhibition in gastrointestinal stromal tumors (GIST) [10], respectively. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.